Colorectal cancer statistics, 2023

IF 503.1 1区 医学 Q1 ONCOLOGY CA: A Cancer Journal for Clinicians Pub Date : 2023-03-01 DOI:10.3322/caac.21772
Rebecca L. Siegel MPH, Nikita Sandeep Wagle MBBS, MHA, PhD, Andrea Cercek MD, Robert A. Smith PhD, Ahmedin Jemal DVM, PhD
{"title":"Colorectal cancer statistics, 2023","authors":"Rebecca L. Siegel MPH,&nbsp;Nikita Sandeep Wagle MBBS, MHA, PhD,&nbsp;Andrea Cercek MD,&nbsp;Robert A. Smith PhD,&nbsp;Ahmedin Jemal DVM, PhD","doi":"10.3322/caac.21772","DOIUrl":null,"url":null,"abstract":"<p>Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. Every 3 years, the American Cancer Society provides an update of CRC statistics based on incidence from population-based cancer registries and mortality from the National Center for Health Statistics. In 2023, approximately 153,020 individuals will be diagnosed with CRC and 52,550 will die from the disease, including 19,550 cases and 3750 deaths in individuals younger than 50 years. The decline in CRC incidence slowed from 3%–4% annually during the 2000s to 1% annually during 2011–2019, driven partly by an increase in individuals younger than 55 years of 1%–2% annually since the mid-1990s. Consequently, the proportion of cases among those younger than 55 years increased from 11% in 1995 to 20% in 2019. Incidence since circa 2010 increased in those younger than 65 years for regional-stage disease by about 2%–3% annually and for distant-stage disease by 0.5%–3% annually, reversing the overall shift to earlier stage diagnosis that occurred during 1995 through 2005. For example, 60% of all new cases were advanced in 2019 versus 52% in the mid-2000s and 57% in 1995, before widespread screening. There is also a shift to left-sided tumors, with the proportion of rectal cancer increasing from 27% in 1995 to 31% in 2019. CRC mortality declined by 2% annually from 2011–2020 overall but increased by 0.5%–3% annually in individuals younger than 50 years and in Native Americans younger than 65 years. In summary, despite continued overall declines, CRC is rapidly shifting to diagnosis at a younger age, at a more advanced stage, and in the left colon/rectum. Progress against CRC could be accelerated by uncovering the etiology of rising incidence in generations born since 1950 and increasing access to high-quality screening and treatment among all populations, especially Native Americans.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"73 3","pages":"233-254"},"PeriodicalIF":503.1000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21772","citationCount":"193","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CA: A Cancer Journal for Clinicians","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.3322/caac.21772","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 193

Abstract

Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. Every 3 years, the American Cancer Society provides an update of CRC statistics based on incidence from population-based cancer registries and mortality from the National Center for Health Statistics. In 2023, approximately 153,020 individuals will be diagnosed with CRC and 52,550 will die from the disease, including 19,550 cases and 3750 deaths in individuals younger than 50 years. The decline in CRC incidence slowed from 3%–4% annually during the 2000s to 1% annually during 2011–2019, driven partly by an increase in individuals younger than 55 years of 1%–2% annually since the mid-1990s. Consequently, the proportion of cases among those younger than 55 years increased from 11% in 1995 to 20% in 2019. Incidence since circa 2010 increased in those younger than 65 years for regional-stage disease by about 2%–3% annually and for distant-stage disease by 0.5%–3% annually, reversing the overall shift to earlier stage diagnosis that occurred during 1995 through 2005. For example, 60% of all new cases were advanced in 2019 versus 52% in the mid-2000s and 57% in 1995, before widespread screening. There is also a shift to left-sided tumors, with the proportion of rectal cancer increasing from 27% in 1995 to 31% in 2019. CRC mortality declined by 2% annually from 2011–2020 overall but increased by 0.5%–3% annually in individuals younger than 50 years and in Native Americans younger than 65 years. In summary, despite continued overall declines, CRC is rapidly shifting to diagnosis at a younger age, at a more advanced stage, and in the left colon/rectum. Progress against CRC could be accelerated by uncovering the etiology of rising incidence in generations born since 1950 and increasing access to high-quality screening and treatment among all populations, especially Native Americans.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
结直肠癌统计,2023年
结直肠癌(CRC)是美国癌症死亡的第二大常见原因。每3年,美国癌症协会根据基于人群的癌症登记的发病率和国家卫生统计中心的死亡率提供CRC统计数据的更新。2023年,大约153020人将被诊断为结直肠癌,52550人将死于该疾病,其中包括19550例病例和3750例50岁以下的死亡。CRC发病率的下降速度从2000年代的每年3%-4%放缓至2011-2019年的每年1%,部分原因是自20世纪90年代中期以来,55岁以下人群的年增长率为1% - 2%。因此,55岁以下人群的病例比例从1995年的11%上升到2019年的20%。自2010年左右以来,65岁以下人群的区域期疾病发病率每年增加约2%-3%,远期疾病发病率每年增加0.5%-3%,扭转了1995年至2005年期间向早期诊断的总体转变。例如,在广泛筛查之前,2019年所有新病例中有60%是晚期,而2000年代中期为52%,1995年为57%。此外,肿瘤也向左侧转移,直肠癌的比例从1995年的27%上升到2019年的31%。从2011年到2020年,CRC死亡率总体上每年下降2%,但在50岁以下的个体和65岁以下的美洲原住民中,CRC死亡率每年增加0.5%-3%。总之,尽管总体上持续下降,但CRC正在迅速转向更年轻、更晚期和左结肠/直肠的诊断。通过揭示1950年以后出生的几代人CRC发病率上升的病因,以及在所有人群中增加获得高质量筛查和治疗的机会,特别是美洲原住民,可以加速防治CRC的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
873.20
自引率
0.10%
发文量
51
审稿时长
1 months
期刊介绍: CA: A Cancer Journal for Clinicians" has been published by the American Cancer Society since 1950, making it one of the oldest peer-reviewed journals in oncology. It maintains the highest impact factor among all ISI-ranked journals. The journal effectively reaches a broad and diverse audience of health professionals, offering a unique platform to disseminate information on cancer prevention, early detection, various treatment modalities, palliative care, advocacy matters, quality-of-life topics, and more. As the premier journal of the American Cancer Society, it publishes mission-driven content that significantly influences patient care.
期刊最新文献
Acute myeloid leukemia management and research in 2025 Cancer care for transgender and gender-diverse people: Practical, literature-driven recommendations from the Multinational Association of Supportive Care in Cancer Preparation and Characterization of Low-Voltage Responsive Nanocomposite Shape-Changing Hydrogels/Carbon Nanofibers With Enhanced Mechanical Properties Introducing Antifouling Properties Onto Janus-Like Decellularized Corneas via Graft-From Zwitterionic Polymers Comparison of Swollen vs. Compounded Cross-linked High-Cis-1,4-Polybutadiene/n-Tetracosane Shape Memory Polymers
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1